Research location

Milan

Milano, Italy

Published trials97

Site observations124

Linked trials published95

Page1 / 2

Research activity in Milan

Milano, Italy

CureCurrent currently publishes aggregate city-level research activity for this location: 97 trials and 124 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Milan

95 linked trials · page 1 of 2

A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate CancerNCT07600554 · 2026-05-27 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19 · 1 site observation

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292 · 2026-01-14 · 1 site observation

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07155187 · 2025-12-10 · 1 site observation

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)NCT06855771 · 2025-09-09 · 1 site observation

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068 · 2025-08-06 · 2 site observations

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson DiseaseNCT06965374 · 2025-06-04 · 2 site observations

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)NCT06961006 · 2025-05-29 · 1 site observation

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06 · 2 site observations

Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis ComplexNCT07304856 · 2025-04-16 · 1 site observation

Implementation and Validation of Instrumented Stair Climb TestNCT06999850 · 2025-04-04 · 1 site observation

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective DatabaseNCT07397585 · 2025-02-25 · 1 site observation

MIRAMACS, Multicenter Italian Study on RAdial Mechanically Assisted Circulatory SupportNCT07458074 · 2025-01-10 · 2 site observations

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung LesionsNCT07401615 · 2024-11-25 · 2 site observations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation

Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.NCT06305390 · 2023-12-04 · 1 site observation

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)NCT07720765 · 2023-10-09 · 1 site observation

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease ProgressionNCT07717567 · 2023-09-12 · 1 site observation

Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of ProgressionNCT05801471 · 2022-05-06 · 1 site observation

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029 · 2021-05-12 · 1 site observation

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyNCT03394365 · 2017-12-29 · 1 site observation

Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory ConcernsNCT07652931 · 2026-08-01 · 1 site observation

NOT_YET_RECRUITING

M1no-Study - Early Identification of Infants With High Type 1 Diabetes Risk for Participation in Primary Prevention TrialsNCT07670143 · 2026-07-01 · 2 site observations

NOT_YET_RECRUITING

Evaluation of the Impact of Virtual Park on Training Motivation in Adult PatientsNCT07616050 · 2026-06-01 · 1 site observation

NOT_YET_RECRUITING

Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica ResonanceNCT07456462 · 2026-05-01 · 1 site observation

NOT_YET_RECRUITING

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate CancerNCT06840535 · 2025-04-08 · 2 site observations

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · 2024-11-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Validation of a Multidimensional Scale for the Detection of Health Needs in People With HIVNCT07077642 · 2024-09-02 · 3 site observations

ENROLLING_BY_INVITATION

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · 2024-07-16 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 · 2024-04-03 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · 2024-01-18 · 3 site observations

ACTIVE_NOT_RECRUITING

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486 · 2023-12-27 · 2 site observations

ACTIVE_NOT_RECRUITING

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · 2023-12-13 · 2 site observations

ACTIVE_NOT_RECRUITING

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)NCT06111586 · 2023-12-11 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382NCT06032546 · 2023-10-12 · 2 site observations

Right Ventricular Dysfunction in Chronic Heart FailureNCT06002321 · 2023-09-01 · 1 site observation

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · 2023-07-20 · 1 site observation

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · 2023-06-15 · 1 site observation

Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological MatricesNCT07480187 · 2023-05-20 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid TumorsNCT05784597 · 2023-04-27 · 1 site observation

Feasibility and Effectiveness of a Mindfulness Program Delivered by Web to Patients During Hospitalization and Caregivers.NCT05623254 · 2023-01-02 · 1 site observation

Retrospective Observational Study on the Use of Advanced Bacterial-binding Dressings (DACC-coated Hydrogel Dressings) in RadiodermatitisNCT07332754 · 2023-01-01 · 1 site observation

Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic DiseasesNCT05766657 · 2022-12-23 · 1 site observation

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsNCT05599984 · 2022-12-05 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerNCT05543629 · 2022-10-04 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.